– Company Presents Poster on Overall Survival
and Long-Term Safety Results from INTRIGUE Study; Second Poster
Presents Analysis from INTRIGUE Patients without Detectable ctDNA
at Baseline –
– Encore Oral Presentation of Results of ctDNA
Analysis of INTRIGUE Phase 3 Study in Second-Line GIST Patients
with Mutations in KIT Exon 11 and 17/18 Which Demonstrated
Substantial Clinical Benefit from QINLOCK but Not Sunitinib –
– Trial-in-Progress Poster Outlines Planned
INSIGHT Pivotal Phase 3 Study of QINLOCK Versus Sunitinib in
Second-Line GIST Patients with KIT Exon 11 and 17/18 Mutations,
Expected to Initiate in the Second Half of 2023 –
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a
biopharmaceutical company focused on discovering, developing, and
commercializing important new medicines to improve the lives of
people with cancer, today announced four poster presentations at
the upcoming 2023 American Society of Clinical Oncology (ASCO)
Annual Meeting, being held in Chicago, Illinois on June 2-6,
2023.
“As we prepare to initiate our INSIGHT pivotal Phase 3 study of
QINLOCK versus sunitinib in second-line GIST patients with KIT exon
11 and 17/18 mutations, we are excited to share details on the
study design and additional supporting data from the INTRIGUE
study. Our exploratory analysis from INTRIGUE using baseline
circulating tumor DNA (ctDNA) showed that QINLOCK provided
clinically meaningful benefit in patients with co-occurring KIT
exon 11 and 17/18 mutations, with a median progression-free
survival of 14.2 months compared to 1.5 months for sunitinib,” said
Matthew L. Sherman, M.D., Executive Vice President and Chief
Medical Officer of Deciphera. “QINLOCK has the clear potential to
become the standard-of-care for these second-line GIST patients and
provide exceptional clinical benefit compared to the current
standard of care.”
Dr. Sherman continued, “We are also pleased to report overall
survival and long-term safety data for our INTRIGUE Phase 3 study.
In the all-patient intent-to-treat population, overall survival was
35.5 months in the QINLOCK arm and 30.9 months in the sunitinib
arm. The favorable safety profile was consistent with our primary
analysis, with fewer patients on QINLOCK experiencing Grade 3/4
treatment-emergent adverse events compared to sunitinib.
Separately, our analysis from the INTRIGUE study showed better
clinical outcomes for patients without detectable ctDNA at
baseline, and among these patients without baseline ctDNA,
ripretinib showed a median PFS of 16.6 months compared to 11.0
months for patients in the sunitinib arm.”
Copies of the posters are currently available on the Company’s
website at www.deciphera.com/presentations-publications.
Presentation details are as follows:
Abstract Number: 11524 Title: Overall survival and
long-term safety in patients with advanced gastrointestinal stromal
tumor previously treated with imatinib: Updated analyses from
INTRIGUE. Presenter: Robin L. Jones, M.D., Consultant
Medical Oncologist, The Royal Marsden NHS Foundation Trust and The
Institute of Cancer Research Session Date: Saturday, June 3
Session Time: 1:15 – 4:15 PM CT Poster Discussion
Session: 4:30 – 6:00 PM CT Key Highlights:
- INTRIGUE is a randomized, open-label, global, multicenter phase
3 study comparing the efficacy and safety of ripretinib vs.
sunitinib in patients with GIST who had disease progression on, or
were intolerant to, first-line treatment with imatinib
- 453 patients were randomized 1:1 to receive ripretinib 150 mg
QD or sunitinib 50 mg QD (4 weeks on/2 weeks off) and were
stratified by KIT mutational status and imatinib intolerance
- 51 of 444 treated patients (11.5%; intent-to-treat population
(ITT)) remain on treatment; 33/223 (14.8%) on ripretinib and 18/221
(8.1%) on sunitinib
- Overall survival (OS) was measured at the second interim
analysis (IA) as of September 1, 2022, with 185 OS events (41%) in
the ITT population and 133/327 (41%) in the KIT exon 11 ITT
population
- OS was similar with ripretinib vs. sunitinib in the ITT
population (median 35.5 months vs. 30.9 months; HR 0.88; 95% CI,
0.66 to 1.18; nominal P = 0.39) and KIT exon 11 ITT population
(median 34.0 months vs. 31.5 months; HR 1.05; 95% CI, 0.75 to 1.48;
nominal P = 0.77)
- PFS on next line of therapy in the second IA was similar with
ripretinib vs. sunitinib in the all patient (AP) ITT population
(median 7.7 months vs. 6.5 months; HR 1.01; 95% CI, 0.76 to 1.34)
and KIT exon 11 ITT population (median 8.2 months vs. 7.5 months;
HR 1.14; 95% CI, 0.81 to 1.59)
- The updated safety profile was consistent with the primary
analysis
- Fewer patients had grade 3/4 treatment-emergent adverse events
(TEAEs) with ripretinib vs. sunitinib (95 [42.6%] vs. 149
[67.4%])
- Dose interruptions, and reductions, and treatment
discontinuations due to TEAEs were lower with ripretinib vs.
sunitinib
- The most common TEAEs of any grade in the ripretinib arm were
alopecia, fatigue, and myalgia, whereas the most common TEAEs of
any grade in patients treated with sunitinib were palmar-plantar
erythrodysesthesia syndrome, diarrhea, and hypertension
Abstract Number: 11536 Title: Outcomes in patients
with advanced gastrointestinal stromal tumor who did not have
baseline ctDNA detected in the INTRIGUE study Presenter:
Jonathan Trent, M.D., Ph.D., Associate Director for Clinical
Research, Sylvester Comprehensive Cancer Center, University of
Miami Health System Session Date: Saturday, June 3
Session Time: 1:15 – 4:15 PM CT Key Highlights:
- An exploratory objective in the INTRIGUE Phase 3 study was to
evaluate anti-tumor efficacy of QINLOCK according to baseline KIT
primary and secondary mutational status using circulating tumor DNA
(ctDNA)
- Data cutoff was September 1, 2021 for all data except OS, which
had a data cutoff of September 1, 2022
- Of the 453 patients in the ITT population, baseline ctDNA was
analyzed in 362 patients for whom evaluable samples were available
- Among 82 patients (22.7%) who had no detectable ctDNA
(ctDNA-ND), 40 were in the ripretinib arm and 42 in the sunitinib
arm
- Among the 280 patients (77.3%) with ctDNA detected (ctDNA-D),
135 were in the ripretinib arm and 145 in the sunitinib arm
- Clinical efficacy was higher in patients with ctDNA-ND vs.
ctDNA-D
- Objective response rate (ORR) rate was higher in patients with
ctDNA-ND (25.6%) vs. ctDNA-D (17.5%)
- Progression-free survival (PFS) was higher in patients with
ctDNA-ND (12.3 months) vs. ctDNA-D (6.8 months), HR 1.81; 95% CI,
1.28 to 2.56; nominal P = 0.0006
- Overall survival (OS) was higher in patients with ctDNA-ND (not
estimable) vs. ctDNA-D (28.9 months), HR 4.69; 95% CI, 2.54 to
8.68; nominal P < 0.0001
- In the ctDNA-ND group, ripretinib demonstrated a numerically
higher PFS vs. sunitinib (median 16.6 months vs. 11.0 months; HR
0.73; 95% CI, 0.39 to 1.39; nominal P = 0.3362) and in the ctDNA-D
group. PFS was comparable between ripretinib and sunitinib (median
6.8 months vs. 6.9 months; HR 1.23; 95% CI, 0.92 to 1.64; nominal P
= 0.1583)
- In the ctDNA-ND group, OS was similar with ripretinib vs.
sunitinib (not estimable for both ripretinib and sunitinib; HR
0.84; 95% CI, 0.25 to 2.75; nominal P = 0.7674) and in the ctDNA-D
group (median 27.7 months vs. 29.5 months; HR 1.05; 95% CI, 0.75 to
1.47; nominal P = 0.7609)
- Patients with ctDNA-ND were younger (median 55.5 years vs. 62.0
years) and had smaller sums of longest diameters of target lesions
vs. patients with ctDNA-D
- Safety was similar between ctDNA groups and consistent with the
primary analysis
- Fewer patients had grade 3/4 TEAEs with ripretinib vs.
sunitinib in both groups (ctDNA-ND, 14 [35.0%] vs. 29 [69.0%];
ctDNA-D, 56 [41.5%] vs. 94 [65.7%])
- Dose interruptions, dose reductions, and treatment
discontinuations due to TEAEs were lower with ripretinib vs.
sunitinib
Abstract Number: TPS11582 Title: INSIGHT: A phase
3, randomized, multicenter, open-label study of ripretinib vs
sunitinib in patients with advanced gastrointestinal stromal tumor
previously treated with imatinib harboring KIT exon 11 + 17 and/or
18 mutations. Presenter: Suzanne George, M.D., Associate
Division Chief, Sarcoma Center, Dana-Farber Cancer Institute
Session Date: Saturday, June 3 Session Time: 1:15 –
4:15 PM CT Key Highlights:
- INSIGHT is an international, Phase 3, randomized, multicenter,
open-label study to evaluate the efficacy of ripretinib vs.
sunitinib in patients with advanced GIST previously treated with
imatinib and who have KIT exon 11 mutations and co-occurring
mutations exclusively in KIT exon 17 and/or 18
- 54 participants will be randomized 2:1 to either ripretinib 150
mg once daily (QD; continuous) or sunitinib 50 mg QD (4 weeks on/2
weeks off) in 6-week cycles
- Patients will receive the study drug until disease progression
determined by independent radiologic review (IRR) using modified
Response Evaluation Criteria in Solid Tumors version 1.1 (mRECIST
v.1.1), unacceptable toxicity, or withdrawal of consent
- Upon disease progression as determined by blinded IRR, patients
in the sunitinib arm may crossover to receive ripretinib
- The primary outcome measure is progression-free survival based
on blinded IRR
Abstract Number: 397784* Title: Mutational
heterogeneity of imatinib resistance and efficacy of ripretinib vs
sunitinib in patients with gastrointestinal stromal tumor: ctDNA
analysis from INTRIGUE Presenter: Sebastian Bauer, M.D.,
Head of Sarcoma Center and Translational Sarcoma Research at the
West German Cancer Center, University Hospital Essen, University
Duisburg-Essen and German Cancer Consortium Session Date:
Saturday, June 3 Presentation Time: 1:54 – 2:00 PM CT Key
Highlights:
- In patients with a KIT exon 11 primary mutation identified by
the planned exploratory analysis from INTRIGUE:
- 52 patients had additional mutations in KIT exon 17/18
only
- 41 patients had additional mutations in KIT exon 13/14
only
- 22 patients had additional mutations in both KIT exon 13/14 and
exon 17/18
- Patients with mutations in KIT exon 11 and exon 17/18 only
derived substantially improved clinical benefit with ripretinib
compared to sunitinib
- Ripretinib demonstrated a median PFS (mPFS) of 14.2 months
compared to 1.5 months for the sunitinib arm (HR 0.22, nominal P
<0.0001)
- Ripretinib demonstrated a confirmed objective response rate
(ORR) of 44.4% (n=12 of 27) compared to 0% for sunitinib (nominal P
= 0.0001)
- OS for the ripretinib arm has not reached a median, while
patients randomized to the sunitinib arm had a median OS (mOS) of
17.5 months (HR 0.34, nominal P = 0.0061)
- Patients with mutations in KIT exon 11 and 13/14 only derived
substantially improved clinical benefit with sunitinib compared to
ripretinib
- Ripretinib demonstrated an mPFS of 4.0 months compared to 15.0
months for the sunitinib arm (HR 3.94, nominal P = 0.0005)
- Ripretinib demonstrated a confirmed ORR of 9.5% compared to 15%
for sunitinib (nominal P = 0.5922)
- Ripretinib demonstrated a mOS of 24.5 months, while mOS for
patients randomized to sunitinib was not estimable (HR 1.75,
nominal P = 0.2085)
* ASCO Plenary Series: Rapid Abstract Update
About the INSIGHT Study
The planned INSIGHT Phase 3 clinical study is a randomized,
global, multicenter, open-label study to evaluate the efficacy and
safety of QINLOCK compared to sunitinib in patients with GIST
previously treated with imatinib with mutations in KIT exon 11 and
17/18 only (excluding patients with mutations in KIT exons 9, 13,
or 14). In the study, 54 patients will be randomized 2:1 to either
QINLOCK 150 mg once daily or sunitinib 50 mg once daily for four
weeks followed by two weeks without sunitinib. The primary endpoint
is PFS as determined by independent radiologic review using
modified RECIST 1.1 criteria. Secondary endpoints include ORR as
determined by independent radiologic review using modified RECIST
1.1 criteria and OS.
About the INTRIGUE Study
The INTRIGUE Phase 3 clinical study is a randomized, global,
multicenter, open-label study to evaluate the efficacy and safety
of QINLOCK compared to sunitinib in patients with GIST previously
treated with imatinib. In the study, 453 patients were randomized
1:1 to either QINLOCK 150 mg once daily or sunitinib 50 mg once
daily for four weeks followed by two weeks without sunitinib. As
previously reported, the study did not achieve the primary efficacy
endpoint of PFS as determined by independent radiologic review
using modified RECIST 1.1 criteria. The statistical analysis plan
included a hierarchical testing sequence that included testing
patients with a KIT exon 11 primary mutation and then in the all
patient intent-to-treat (AP) population. In patients with a KIT
exon 11 primary mutation (n=327), QINLOCK demonstrated an mPFS of
8.3 months compared to 7.0 months for the sunitinib arm (HR 0.88,
p=0.360). Although not formally tested due to the rules of the
hierarchical testing sequence, in the AP population QINLOCK
demonstrated a mPFS of 8.0 months compared to 8.3 months for the
sunitinib arm (HR 1.05, nominal p=0.715). QINLOCK was generally
well tolerated. Fewer patients in the QINLOCK arm experienced Grade
3-4 treatment-emergent adverse events compared to sunitinib (41.3%
vs. 65.6%).
About Deciphera Pharmaceuticals
Deciphera is a biopharmaceutical company focused on discovering,
developing, and commercializing important new medicines to improve
the lives of people with cancer. We are leveraging our proprietary
switch-control kinase inhibitor platform and deep expertise in
kinase biology to develop a broad portfolio of innovative
medicines. In addition to advancing multiple product candidates
from our platform in clinical studies, QINLOCK® is Deciphera’s
switch-control inhibitor for the treatment of fourth-line GIST.
QINLOCK is approved in Australia, Canada, China, the European
Union, Hong Kong, Israel, Macau, New Zealand, Switzerland, Taiwan,
the United Kingdom, and the United States. For more information,
visit www.deciphera.com and follow us on LinkedIn and Twitter
(@Deciphera).
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, our expectations
and timing regarding our planned Phase 3 INSIGHT study of QINLOCK
versus sunitinib in second-line GIST patients with mutations in KIT
exon 11 and 17/18, plans to initiate the INSIGHT study in the
second half of 2023, our ability to offer clinically meaningful
benefit for second-line GIST patients based on mutational drivers
of their disease, and the potential for QINLOCK to become the
standard-of-care for second-line GIST patients with mutations in
KIT exon 11 and 17/18. The words “may,” “will,” “could,” “would,”
“should,” “expect,” “plan,” “anticipate,” “intend,” “believe,”
“estimate,” “predict,” “project,” “potential,” “continue,” “seek,”
“target” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Any forward-looking
statements in this press release are based on management’s current
expectations and beliefs and are subject to a number of risks,
uncertainties and important factors that may cause actual events or
results to differ materially from those expressed or implied by any
forward-looking statements contained in this press release,
including, without limitation, our ability to successfully
demonstrate the efficacy and safety of our drug or drug candidates,
the preclinical or clinical results for our product candidates,
which may not support further development of such product
candidates, comments, feedback and actions of regulatory agencies,
our ability to commercialize QINLOCK and execute on our marketing
plans for any drugs or indications that may be approved in the
future, the inherent uncertainty in estimates of patient
populations, competition from other products, our ability to obtain
and maintain reimbursement for any approved product and the extent
to which patient assistance programs are utilized and other risks
identified in our Securities and Exchange Commission (SEC) filings,
including our Quarterly Report on Form 10-Q for the quarter ended
March 31, 2023, and subsequent filings with the SEC. We caution you
not to place undue reliance on any forward-looking statements,
which speak only as of the date they are made. We disclaim any
obligation to publicly update or revise any such statements to
reflect any change in expectations or in events, conditions or
circumstances on which any such statements may be based, or that
may affect the likelihood that actual results will differ from
those set forth in the forward-looking statements.
The Deciphera logo, QINLOCK, and the QINLOCK logo are registered
trademarks and Deciphera is a trademark of Deciphera
Pharmaceuticals, LLC.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230525005807/en/
Investor Relations: Maghan Meyers Argot Partners
Deciphera@argotpartners.com 212-600-1902
Media: David Rosen Argot Partners
david.rosen@argotpartners.com 212-600-1902
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From May 2024 to Jun 2024
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Jun 2023 to Jun 2024